搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 1 小时
时间不限
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
28 分钟
Actinium的Iomab-B在III期急性髓系白血病试验中显示前景
NEW YORK – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) 分享了其III期SIERRA试验的Iomab-B结果。Iomab-B是一种靶向放射疗法,旨在为骨髓移植(BMT)做准备,可能治愈复发或难治性急性髓系白血病(r/r AML)。试验显示,Iomab-B显著提高了老年患者的持久完全缓解(dCR)和无事件生存期(EFS)。 SI ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Kentucky judge fatally shot
Secret Service probing post
FCC chair denies Trump call
Cancels appearance w/ Duda
Human remains found in SUV
Boy kills bear, saves father
COVID, Wuhan market link
Ban called for in TX schools
Families lose appeal
Hold campaign event in MI
Vows to remain in race
To get a second moon
Israel strikes Hezbollah
To visit US next week
Brazil threatens daily fines
Dow, S&P hit record highs
Hails economic progress
Existing home sales drop
To receive Holbrooke award
160M euros to Ukraine
UN backs Palestine
FTC on privacy controls
Retires after 17 seasons
EU warns Apple
Man charged for threats
Collapse hazard recall
Overdose deaths drop in US
Gun case sentencing delay
NYC subway joyride arrest
PGA welcomes LIV players
Makes MLB history
反馈